Coherus, Junshi Biosciences Get FDA Complete Response Letter (1) - Bloomberg Law
(Updates to add CHRS shares and context.) Shanghai Junshi Biosciences and Coherus BioSciences received a complete response letter from the U.S. Food and Drug Administration for use of the PD-1 in...
Read more